BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Press Releases

  Ionis announces pricing of $500.3 million public offering

  September 10, 2024

   · 

  4 min read
• Press Releases

  Santhera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern Europe

  September 10, 2024

   · 

  6 min read
• Press Releases

  Curium Announces PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – Is Now Available in Spain

  September 10, 2024

   · 

  2 min read
• Press Releases

  Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

  September 10, 2024

   · 

  4 min read
• Press Releases

  Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

  September 10, 2024

   · 

  9 min read
• Press Releases

  TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization

  September 10, 2024

   · 

  6 min read
• Press Releases

  Mural Oncology to Host First Virtual Investor Day on September 26, 2024

  September 10, 2024

   · 

  6 min read
• Press Releases

  Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

  September 10, 2024

   · 

  10 min read
• Press Releases

  C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen

  September 10, 2024

   · 

  4 min read
• Press Releases

  ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery

  September 10, 2024

   · 

  3 min read